BioNTech Results Presentation Deck slide image

BioNTech Results Presentation Deck

Expansion into New Class of Precision Antibacterials with PhagoMed Acquisition D ........ 36 ● ● ● ● ● ● PhagoMed: based in Vienna, Austria Pioneering new class of precision antibacterials called synthetic lysins. Lysins are highly bactericidal phage-derived enzymes that cleave the bacterial cell wall Potential to address difficult to target pathogens & global challenge of antimicrobial resistance. Lysin Builder in silico technology platform based on proprietary algorithms Designed to rapidly produce recombinant natural lysins against a wide range of pathogens Optimization for potency, stability and manufacturing yield Total consideration can reach up to €150.0 m consisting of upfront consideration of €50.0 m (less) acquired debt) with the possibility of the selling shareholders earning up to an additional ~ €100.0 m Transaction closed in Q3 Forms BioNTech's new R&D hub for precision antibacterials operating as BioN Tech R&D Austria mRNA Vaccines Acquisition expands Infectious Disease Toolkit: | mRNA Encoded Antibodies .... Precision Anti-bacterials BIONTECH
View entire presentation